Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 1, 2004. The report details specific corporate actions regarding share buybacks and changes in directors' interests in ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share repurchase transaction:
- Shares Purchased: 435,000 Ordinary shares.
- Purchase Price: 1,143.5077 pence per share.
- Treasury Holdings: 16,262,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,917,230,600 shares (excluding Treasury shares).
Material Changes
The filing reports the following material changes compared to the prior period:
- Share Repurchase: On May 28, 2004, the Company purchased 435,000 shares under authority granted at the Annual General Meeting on May 17, 2004.
- Employee Trust Transfers: The GlaxoSmithKline Employee Trust transferred a total of 74,986 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 (49,406 shares on May 26 and 25,580 shares on May 27).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the execution of the share buyback and the administrative transfer of shares from the employee trust.
Investor Verification Checklist
- Verify the total cost of the 435,000 share repurchase against the disclosed price of 1,143.5077 pence.
- Confirm the updated total number of shares in issue (5,917,230,600) and Treasury holdings (16,262,000) in subsequent filings.
- Review the impact of the 74,986 shares transferred from the GSK Trust on the total outstanding share count.
- Note that this filing does not contain quarterly or annual financial performance data.